US2012196878A1PendingUtilityA1
Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders
Individually held — no corporate assignee on recordPriority: Sep 24, 1998Filed: Aug 30, 2011Published: Aug 2, 2012
Est. expirySep 24, 2018(expired)· nominal 20-yr term from priority
A61P 37/00A61K 31/522G01N 2800/245Y10T436/147777Y10T436/141111Y10T436/142222A61P 1/04G01N 2800/06G01N 2800/065G01N 33/564G01N 2800/24A61P 1/00A61K 31/52G01N 33/94
59
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes the step of determining the level of one or more 6-mercaptopurine metabolites in the patient having an immune-mediated gastrointestinal disorder.
Claims
exact text as granted — not AI-modified1 . A method of optimizing therapeutic efficacy of 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder, comprising:
(a) administering a 6-mercaptopurine drug to a subject having said immune-mediated gastrointestinal disorder; and (b) determining a level of 6-thioguanine in said subject having said immune-mediated gastrointestinal disorder,
wherein a level of 6-thioguanine less than a level corresponding to about 230 pmol per 8×10 8 red blood cells indicates a need to increase the amount of 6-mercaptopurine drug subsequently administered to said subject and
wherein a level of 6-thioguanine greater than a level corresponding to about 400 pmol per 8×10 8 red blood cells indicates a need to decrease the amount of 6-mercaptopurine drug subsequently administered to said subject.
2 - 34 . (canceled)Join the waitlist — get patent alerts
Track US2012196878A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.